Jan 25 (Reuters) - Meridian Bioscience Inc:
* MERIDIAN BIOSCIENCE REPORTS FIRST QUARTER 2018 OPERATING RESULTS, DECLARES REGULAR FIRST QUARTER CASH DIVIDEND, AND REAFFIRMS FISCAL 2018 GUIDANCE
* Q1 NON-GAAP EARNINGS PER SHARE $0.15 * Q1 GAAP EARNINGS PER SHARE $0.15 * Q1 REVENUE $52.3 MILLION VERSUS I/B/E/S VIEW $49 MILLION * Q1 EARNINGS PER SHARE VIEW $0.15 -- THOMSON REUTERS I/B/E/S
* REAFFIRMS FY 2018 NON-GAAP EARNINGS PER SHARE VIEW $0.65 TO $0.68
* REAFFIRMS FY 2018 GAAP EARNINGS PER SHARE VIEW $0.59 TO $0.62
* SEES FY 2018 REVENUE $207 MILLION TO $212 MILLION * ‍CONTINUING TO WORK WITH FDA REGARDING USE OF VENOUS BLOOD WITH MAGELLAN‘S LEADCARE TESTING SYSTEMS​
* ‍MAGELLAN LEAD TESTING BUSINESS UNIT REVENUES DECLINED BY 20% IN QUARTER YEAR-OVER-YEAR​
* ‍ANTICIPATE A REBOUND IN MAGELLAN BUSINESS IN Q2 AND A RETURN TO GROWTH FOR QUARTER​
* ‍ILLUMIGENE CMV, FIRST MOLECULAR TEST FOR CYTOMEGALOVIRUS, IS TARGETED TO LAUNCH LATE IN CALENDAR YEAR 2018​
* ‍BUSINESS OUTLOOK FOR FISCAL 2018 REMAINS UNCHANGED​ * FY2018 EARNINGS PER SHARE VIEW $0.66, REVENUE VIEW $207.1 MILLION -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:
 